Abstract: Bruton's tyrosine kinase (BTK) inhibitors are novel drugs targeted for the treatment of B-cell lymphoma. BTK inhibitors have produced strong curative effects, especially for mantle cell lymphoma (MCL), chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SSL), and Waldenström's macroglobulinemia (WM). However, the adverse effect of bleeding has gradually been noted with the widespread use of BTK inhibitors in clinical practice. Bleeding events are caused by the off-target effects of BTK inhibitors, which affect platelet function through multiple signaling pathways during use. Bleeding affects patient treatment and threatens their quality of life. As such, the clinical management of bleeding should be strengthened. This paper provides a review of the mechanisms of action and clinical management of bleeding caused by BTK inhibitors.